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ABSTRACT 
 
A substantial portion of the current research on lower urinary tract dysfunction is focused on 
afferent mechanisms.  The main goals are to define and modulate the signaling pathways by 
which afferent information is generated, enhanced and conveyed to the central nervous system.  
Alterations in bladder afferent mechanisms are a potential source of voiding dysfunction and an 
emerging source for drug targets.  Established drug therapies such as muscarinic receptor 
antagonists, and two emerging therapies, 3-adrenergic receptor agonists and botulinum toxin 
type-A, may act partly through afferent mechanisms.  This review focuses on these two new 
principles and new and established methods for determining their sites of action.  It also provides 
brief information on the innervation of the bladder, afferent receptors and transmitters and how 
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these may communicate with the urothelium, interstitial cells and detrusor smooth muscle to 
regulate micturition.  Peripheral and central mechanisms of afferent sensitization and myogenic 
mechanisms that lead to detrusor overactivity, overactive bladder symptoms and urgency 
sensations are also covered.  This work is the result from ‘Think Tank’ presentations, and the 
lengthy discussions that followed, at the 2010 International Consultation on Incontinence 
Research Society meeting in Bristol, UK. 
 
Key words: 3-adrenergic receptor agonists, bladder afferents, botulinum toxin type-A, optical 
mapping. 
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INTRODUCTION 
 
Innervation of the urinary bladder and urethra. The coordination between the urinary bladder 
and the outlet (the bladder neck, urethra and urethral sphincters) is mediated by a complex neural 
control system located in the brain, spinal cord and peripheral ganglia as depicted in figure 1.  
This includes innervation through sympathetic (hypogastric), parasympathetic (pelvic) and 
somatic (pudendal) nerves.  Sympathetic nerves in the human and mouse spinal cords originate 
in the T11-L2 segments
1.  They run through the ganglia in the inferior mesenteric plexus and then 
the hypogastric nerves to enter the pelvic plexus and then the base of the bladder and urethra2.  
Parasympathetic nerves arise from the S2-S4 (L6-S2 in mice) spinal segments and travel in the 
sacral roots and pelvic nerves through ganglia in the pelvic plexus and into the bladder wall.  
Somatic nerves innervating the striated muscle of the external urethral sphincter arise from S2-S4 
(L6 in mice)
3 motor neurons in Onuf’s nucleus and pass through the pudendal nerves. 
 
Afferent fiber types and distribution in the bladder wall. Sympathetic, parasympathic and 
somatic nerves to the bladder may all contain sensory (afferent) nerves.  In the urinary bladder 
there are both A and C-fibers afferent populations, which have been demonstrated to consist 
of low and high threshold mechanosensitive fibers4.  The localization and characteristics of these 
fibers in the bladder has been investigated in various animal models5, 6 and a summary of the 
results is described in figure 27.  There is also a class of ‘silent’ C-fibers that are not excited by 
known physiological stimuli even at intensities that can damage the innervated tissue8.  These 
fibers are particularly numerous in the bladder and other viscera and may constitute up to 90% of 
the C-fibers9.  It is suggested that these fibers are nociceptors with their orthodromic activity 
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summing spatially and temporally at second order neurons to contribute to different pain states8.  
This correlates with the activity of C-fibers increasing in pathological conditions including 
bladder outlet obstruction10, spinal cord injury11, diabetes12, cystitis13 and colitis14.  Therefore, 
specific drug targeting of sensitized afferents could lead to more effective treatments. 
 
Peripheral and central afferent sensitization. Alterations in bladder afferent mechanisms may 
contribute to voiding dysfunction in pathologies such as spinal cord injury or outlet obstruction.  
Accordingly, drug therapies such as muscarinic receptor antagonists, 3-adrenergic receptor 
agonists and botulinum toxin type-A (BTX-A) injections may act partly through suppression of 
afferent activity.  One mechanism for alteration involves neuronal remodeling and sprouting.  
Following spinal cord injury, there can be changes in the function or architecture of afferent 
terminals in the periphery or the spinal cord.  It has recently been demonstrated that there is 
increased sprouting of unmyelinated calcitonin gene-related peptide containing nerves in the 
lumbosacral region of the cord of spinalized rats15, 16.  This regeneration and remodeling of 
afferent nerves is believed to facilitate the emergence of reflex bladder activity as well as 
contribute to the development of visceral pain.  The functional remodeling of afferent nerves 
may be driven by a variety of neurotrophic factors including nerve growth factor.  An increase in 
the responsiveness of dorsal root neurons to noxious stimuli and changes in gene expression can 
cause a decrease in afferent thresholds that characterize the phenomenon of central sensitization.  
Stimuli that can cause central sensitization include tissue inflammation and nerve injury where 
there is repeatable or intense C-fiber stimulation.  Primary afferents excited by a variety of strong 
noxious stimuli release neurotransmitters (including glutamate, tachykinins, etc.) antidromically 
from the peripheral terminals as well as in the spinal cord dorsal horn.  Neurotransmitters 
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released in the latter case can sensitize second or third order sensory neurons leading to the 
transmission of noxious signals to the brain with an intact spinal cord.  In the bladder, 
nociceptive C-fibers can become sensitive to mechanical stimulation in pathology and contribute 
to incontinence. 
 
SITES OF ACTION OF 3-RECEPTOR AGONISTS AND BTX-A IN THE BLADDER 
 
Role of the urothelium in afferent activation.  Stretch of the mucosa (comprised of the 
urothelium and suburothelium) generates the release of several molecules17, 18 that could have a 
role in afferent signaling, including ATP, acetylcholine (ACh) and nitric oxide (NO).  This 
provides a mechanism that links bladder filling to afferent excitation.  The transmitters could act 
directly on afferent nerve fibers or indirectly through suburothelial interstitial cells (IC).  Recent 
studies demonstrate that NO synthase exists in the rat urinary bladder and that its substrate, L-
arginine, can inhibit both mechanosensitive A- and C-fiber afferents19.  The role of ATP has 
been investigated more extensively and it has been demonstrated that P2X2/3 receptor knockout 
mice display reduced afferent firing in response to distension and have increased bladder 
volumes20, 21.  In animal studies where ATP was intravesically instilled, findings suggest that 
there are direct effects mainly on capsaicin-sensitive C-fibers22.  These studies suggest that 
urothelial ATP normally plays a part in the initiation of micturition.  The release of ATP has 
been shown to increase in various pathologies, including spinal cord injury23, 24 and painful 
bladder syndrome25, 26.  Moreover, agents such as BTX-A that reduce bladder overactivity 
normalize enhanced ATP release24. 
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3-receptor agonists and BTX-A for treating bladder overactivity.  There are several drug 
therapies used or under investigation for ameliorating the symptoms of bladder overactivity and 
overactive bladder (OAB) symptoms.  Anti-muscarinics are the standard drug treatment and have 
many sites of action in the lower urinary tract (LUT).  They were initially thought to act by 
inhibiting contractile activation of the detrusor during voiding by blocking activation of the M3 
receptor pathway27.  However, the major effect of anti-muscarinics is during the filling phase, 
when parasympathetic nerves are silent.  This suggests that anti-muscarinics may instead be 
affecting the sensory function of the bladder.  This idea is supported by studies that demonstrated 
muscarinic receptor expression on the urothelium28, 29, IC30 and bladder afferent DRGs31.  Direct 
inhibition of afferent nerves by the antimuscarinic receptor antagonists, oxybutynin 
(nonselective) and darifenacin (M3 selective) have been demonstrated in the rat through single-
unit measurement of A- and C-fiber afferents32, 33.  Animals chronically treated with 
antimuscarinics showed decreased spinal cord c-fos expression 34, also suggesting that these 
drugs can affect afferent nerve function. 
 
An emerging treatment for bladder overactivity is 3-receptor agonists.  It has been shown that 
3-receptors are highly expressed in the bladder, particularly in the detrusor and the urothelium35.  
Activation of these receptors is believed to reduce the symptoms of bladder overactivity by 
relaxing the detrusor smooth muscle.   However, whether this is the sole mechanism of action is 
not known.  Studies have suggested 3-receptor agonists may inhibit the firing of 
mechanosensitive afferent nerves in the bladder36.  In addition, 3-receptors may influence 
transmitter release from the urothelium as -receptor stimulation can induce NO release37. 
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BTX-A has also shown promise as a therapy for the symptoms of bladder dysfunction in patients 
with neurogenic detrusor overactivity and possibly other conditions such as idiopathic 
overactivity and painful bladder syndrome38.  Although the procedure for BTX-A administration 
is invasive, the benefit of this treatment is that it is long-acting, with effects lasting several 
months, and may be repeated several times39.  BTX-A was thought to act by inhibiting muscle 
contractions through block of neurotransmitter release.  However, it has been found that BTX-A 
does not affect the spontaneous intrinsic contractions of the detrusor 40, suggesting therapeutic 
effects are mediated from a different site.  There is evidence that BTX-A inhibits bladder sensory 
pathways that could contribute to storage symptoms.  Animal studies have shown BTX-A can 
decrease transmitter release, such as ATP and NO, from the urothelium23 and neuropeptide 
release from bladder afferents41.  Thus, the effects on afferent nerves may contribute to the 
beneficial aspects of BTX-A treatment, even in neurogenic bladder overactivity, where the main 
goal is to reduce the contractility of the bladder.  Overall, there are multiple sites and 
mechanisms of action for the mentioned agents.  The effectiveness of these treatments depends 
upon selectivity for the urinary bladder as well as minimizing undesirable side effects. 
 
 
NEW APPROACHES FOR STUDYING DRUG EFFECTS ON AFFERENT ACTIVITY 
 
Neurogenic and myogenic bladder overactivity. Animal models exhibiting neurogenic and 
myogenic bladder overactivity include new bladder and colon irradiation-induced overactivity 
models developed by the corresponding author’s laboratory (figure 3A and B) and the 
established spinal cord transected (SCT) mouse (figure 3C).  While all three of these models 
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exhibit bladder overactivity when studied using cystometry, when the bladders are excised and 
studied as whole sheets, only those from SCT mice exhibit intrinsic detrusor contractions (figure 
3Eiv).  This suggests that irradiation-induced overactivity involves only central sensitization 
(figure 3D-E/ii-iii).  Urinary diversion prior to transection prevents the development of 
overactivity (not shown), demonstrating the importance of detrusor-sphincter dyssynergia, 
urinary retention and bladder overdistension in the development of myogenic overactivity. 
 
Simultaneous measurements of afferent nerve firing and spontaneous bladder contractions. In 
order to investigate the multiple components contributing to bladder overactivity, we have 
developed an in vitro method which involves isolating the bladder with the associated spinal 
roots that make up the pelvic and hypogastric nerves.  This preparation allowed us to record 
single-unit afferent nerve firing simultaneously with tension measurements of intrinsic bladder 
contractions and optical maps of their initiation sites (figure 4).  Using this method, we have 
demonstrated that there is direct correlation between spontaneous contractions and afferent nerve 
firing in the bladders of SCT mice (figure 4D)42.  Accordingly, this approach allows us to 
evaluate the sites of action and therapeutic benefits of agents such as β3-recptor agonists and 
BTX-A in decreasing afferent firing and intrinsic bladder contractions. 
 
Effects of 3-receptor agonists and BTX-A on afferent sensitization, neuropeptide release and 
detrusor overactivity. The 3-receptor is highly expressed in the bladder, particularly on smooth 
muscle43 and activation of this subtype leads to relaxation and decreased intrinsic contractile 
activity.  3-receptors are also expressed on other cell types including urothelium44, IC 35 and 
afferent nerve terminals35.  However, a direct effect on decreasing afferent sensitization and 
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neuropeptide release has not yet been reported.  In part, this is because intrinsic bladder 
contractions, as shown in figure 4D, can directly stimulate afferent nerves42.  This makes it 
difficult to determine if the effects of 3-receptor agonists on afferent firing are direct, or an 
indirect consequence of smooth muscle relaxation.  Accordingly, we have developed another 
approach to address this issue that was utilized to obtain the unpublished findings in figure 5.  
These data suggest that the 3-receptor agonist, BRL37344, can reduce afferent firing in bladder 
sheets from SCT mice through a direct action on these nerves.  After obtaining single unit 
activity, in response to stepper motor-controlled stretches, addition of the 3-receptor agonist 
decreased afferent firing without changing the smooth muscle tension profile (figure 5B).  As 
indicated by the red arrow pointing to the tension profile in figure 5A, the effects of spontaneous 
bladder contractions on afferent firing can be discerned during controlled stretches.  The length, 
duration and rate of these stretches typically range from 10-20% of resting length, 1-30 sec and 
1-100 m/sec, respectively.  However, these parameters can be set to mimic the slow rates of 
normal bladder filling.  The addition of a 3-selective receptor antagonist, L-748,377, enhanced 
afferent firing over controls (figure 5C), unmasking activity that was most likely inhibited by 
endogenous norepinephrine released from sympathetic nerves. 
 
BTX-A has been utilized in numerous clinical trials as a therapeutic agent to reduce neurogenic 
bladder overactivity.  BTX-A is classically thought to act upon parasympathetic cholinergic 
nerve terminals.  The toxin selectively cleaves SNAP-25 which inhibits ACh release thereby 
reducing muscle contractility39.  However, by using the mouse bladder-pelvic nerve approach in 
figure 4 with BTX-A, it was determined that this agent can also directly inhibit afferent nerve 
firing (not shown).  Since BTX-A has an onset of action of days, bladders were injected with the 
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toxin in vivo, and then excised and studied 48-72 hours later.  BTX-A was injected at 2 to 3 sites 
from the serosal side along with a blue dextran dye of comparable molecular weight (150 kDa) to 
track its distribution.  It was determined that half the bladder wall could be filled with BTX-A 
(figure 6A) permitting changes in activity to be studied in treated and untreated sides of the same 
bladder (figure 6B) offering a built-in control.  It was determined that BTX-A decreased the 
firing frequency of bladder afferent nerves in response to stretch and spontaneous contractions 
(not shown). 
 
Neuropeptide release from afferent nerves could also be studied in the bladder-pelvic nerve sheet 
preparations.  This was accomplished by using the detrusor as a sensor and optically imaging 
neuropeptide evoked action potentials (figure 7A) while measuring tension generation in 
response to capsaicin (figure 7B).  The bladder in this figure was injected on the left side 
(inscribed by the blue box) with BTX-A (1 Unit).  Low dose (10-150 nM) capsaicin must be 
used to permit multiple applications before desensitization.  Electrical field or bipolar stimulation 
cannot be used because they evoke much larger efferent mediated responses which mask 
neuropeptide release.  The response could be blocked with a cocktail of NK1/NK2 receptor 
antagonists (not shown).  In rodents, NK1 and NK2 receptors are located on detrusor smooth 
muscle, and NK2 receptors are located on afferent nerve terminals
45.  In humans, NK1 receptors 
are on afferent terminals and NK2 receptors are on muscle
45, 46.  This same approach can be used 
to test the effect of 3-receptor agonists on neuropeptide release, only the drug must be bath 
applied and will affect the whole sheet preparation (not shown). 
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Potential mechanism for the actions of 3-receptor agonists and BTX-A in the bladder wall.  
We hypothesize that antimuscarinic agents exert an effect on signaling pathways linking bladder 
wall stretch and the release of transmitters and afferent nerve activation, as shown in figure 8.  
Urothelial ACh may act in an autocrine fashion to promote ATP release or act on downstream 
signaling pathways, and antimuscarinic agents disrupt these processes.  Furthermore, in afferent 
nerves, blockade of muscarinic receptors could decrease neuropeptide release reducing irritative 
symptoms as well as afferent sensitization.  Decreasing IP3 levels may inhibit the opening of 
voltage-gated Ca2+ channels and peptide release.  This, in turn, could decrease positive feedback 
on neurokinin 2 (NK2) receptors in rodents and NK1 receptors in humans.  This would remove 
inhibition on K+ channels causing hyperpolarization and decreased afferent firing47, 48. 
 
3-receptor agonists may produce similar results in IC and afferent nerves, working through 
increased protein kinase A (PKA), which inhibits elevations in intracellular Ca2+ (figure 8B).  In 
UC, 3-receptor agonists also increase NO production which may diffuse to and disrupt IC 
coupling and the drive on intrinsic spontaneous contractions.  In the urethra, NO produces 
smooth muscle relaxation.  Its action in the detrusor is questionable because the levels of cyclic 
guanosine monophosphate (cGMP) generated in response to exogenously applied NO are 
extremely low 49.  The action of BTX-A in UC may decrease ATP release (figure 8C) which is 
vesicular, but not ACh release which is non-vesicular 50.  BTX-A may also decrease ACh and 
prostaglandin (PG) release from IC.  In afferent nerves, it may decrease neuropeptide release 
and, therefore, afferent sensitization. 
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CONCLUSION 
The discussed topics indicate there are still many unknown factors related to afferent 
mechanisms and methods for treating sensory disorders of the bladder.   Much of the emphasis 
was on new therapeutic options, namely 3-receptor agonists and BTX-A, and their potential 
sites and mechanisms of action.  In summary, it is necessary to use new approaches and 
techniques, some of which were discussed in this review, in order to further our understanding of 
the sensory function of the LUT and improve upon treatment methods. 
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FIGURE LEGENDS 
 
Figure 1. Innervation of the LUT. 
 
Figure 2. Classes and distribution of afferent nerves in the LUT.  A) The distribution of the 
different classes of afferent fibers in the bladder wall and urethra.  B) Four types of 
mechanosensitive fibers were identified in the pelvic nerve by stretch, stroke and probing of the 
bladder.  C) Proportions of afferent fiber types recorded in the pelvic nerve.  D) Distribution of 
low- and high-threshold receptive fields of pelvic nerve muscle fibers based on responses to 
stretch.  E) Distribution of receptive fields of the four classes of pelvic nerve fibers.  The data 
and illustrations in B to E are adapted from Xu and Gebhart 5. 
 
Figure 3. Animal models of neurogenic and myogenic bladder overactivity. Bladder 
irradiation-induced (A) and colon irradiation-induced (B) neurogenic overactivity models.  C) 
Spinal cord transection (T8-T9), a mouse model for neurogenic and myogenic bladder 
overactivity.  D) In vivo cystometry data.  E) In vitro bladder sheet tension measurements.  Live 
animal photos by permission of the IACUC, University of Pittsburgh. 
 
Figure 4. Simultaneous recordings of afferent nerve activity and spontaneous bladder 
contractions.  A) Optical mapping system showing the light source, filters and photodiode array 
cameras above a whole bladder sheet-nerve preparation. B) Spontaneous intracellular Ca2+ 
transients recorded from the bladder sheet.  C) Isochronal map derived from the data in B, where 
the white area corresponds to the initiation site for spontaneous contractions. D) Large 
spontaneous contractions in a SCT mouse bladder stimulate afferent nerve firing. E) Small 
spontaneous contractions in a control bladder do not. 
 
Figure 5. Effects of β3-adrenergic agonists on afferent activity. Single unit activity in 
response to stretch is decreased by addition of a 3 agonist (BRL37344) to a SCT mouse bladder 
sheet (B).  The 3-antagonist, L-748,337, abolished the effect of BRL37344 (C). 
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Figure 6. BTX-A injected mouse bladder. A) A mouse bladder injected over half its wall 
surface with BTX-A (1 Unit) and blue dextran dye of comparable weight (150 kDa) to track its 
distribution.  B) The bladder after excision with the associated pelvic nerves mounted in a 
recording chamber. 
 
Figure 7. Measurement of neuropeptide release from afferent nerves. A) Optical action 
potentials and B) tension generation in response to capsaicin-evoked neuropeptide release in a 
SCT mouse bladder sheet. 
 
Figure 8. Hypotheses for the pathways mediating the effects of M3-muscarinic receptor 
antagonists, 3-adrenergic receptor agonists and BTX-A in the LUT. 
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